A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
Clinical trial NCT05286619 · RECRUITING
Trial details
- NCT number
- NCT05286619
- Sponsor
- University of Malaya
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-22
- Primary completion
- 2025-12-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.